Antiva Biosciences   Report issue

For profit Phase 1 Phase 2
Founded: Del Mar CA United States (2012)

Organization Overview

First Clinical Trial
2017
NCT03202992
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Antiva Biosciences

Active Ingredients

Drugs in Phase 2 Trials (1)

abi-2280 (1 trial)

Drugs in Phase 1 Trials (1)

abi-1968 (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anus Neoplasms (Phase 1)

Carcinoma in Situ (Phase 1)

Cervical Intraepithelial Neoplasia (Phase 1)

Communicable Diseases (Phase 1)

Infections (Phase 1)

Neoplasms (Phase 1)

Papilloma (Phase 1)

Papillomavirus Infections (Phase 1)

Squamous Intraepithelial Lesions of the Cervix (Phase 1)

Uterine Cervical Dysplasia (Phase 1)

Uterine Cervical Neoplasms (Phase 1)

Virus Diseases (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 2